Skip to main content
European Commission logo print header

Psychiatric Ratings using Intermediate Stratified Markers 2

Project description

Novel biomarkers for stratifying neuropsychiatric disorders

Classification of neuropsychiatric disorders such as schizophrenia, where core biology remains relatively unknown, mainly depends on neuroimaging biomarkers and clinical endpoints. The use of quantitative biomarkers would not only assist in disease classification but also help drug development efforts. The EU-funded PRISM 2 project will capitalise on the knowledge generated by its predecessor PRISM 1 project on diagnostic and social functioning biomarkers for schizophrenia and Alzheimer’s disease and aim to extend it to major depressive disorders. The goal is to identify reliable biomarkers to help in the diagnosis and personalised treatment of neuropsychiatric disorders.


The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.


Net EU contribution
€ 1 024 422,50
Broerstraat 5
9712CP Groningen

See on map

Noord-Nederland Groningen Overig Groningen
Activity type
Higher or Secondary Education Establishments
Other funding
€ 600 000,00

Participants (17)